MDDI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Five Events That Disrupted the Diabetes Market

  • These five developments—ranging from business moves to technology introductions—have redefined and reshaped the diabetes market. 

    Image Courtesy of Silviarita/Pixabay
  • The Rise of Dexcom

    San Diego-based Dexcom was founded in 1999, but the company’s technology stems from research conducted about 51 years go by the University of Wisconsin to determine if the body would not reject an implanted sensor. The research led to Dexcom’s continuous Glucose Monitoring System and the company maintaing a dominant position in the CGM market.

    Image Courtesy of Dexcom
  • Google Enters Healthcare

    Ten years ago, Google was thought of as nothing more than a search engine. However in 2014 the company partnered with Novartis to develop contact lenses that could detect insulin levels in patients. Since then Google has spun off its lifesciences division - now called Verily. The spinoff  has been highly visible in healthcare, especially in the diabetes market, forming partnerships and creating subsidiaries to develop technologies to treat the disease.


    Image Courtsey of 422737/Pixabay
  • Johnson & Johnson Contemplates Selling Diabetes Businesses

    Johnson & Johnson made headlines when the New Brunswick, N.J.-based company announced it was considering the sale of its diabetes unit in 2017, due the unit underperforming. JNJ pushed the envelope a bit farther when it announced last year that it  would exit the insulin pump market. The company turned over its pump customers to Dublin-based Medtronic. 

    Image Courtesy of Maialisa-Pixabay
  • Medtronic receives FDA approval ‘artificial pancreas’

    For years Medtronic had been touting the development of a closed loop device. However it was until Sept. of 2016, the Dublin-based company finally brought this goal to furition, when it received FDA approval for its Minimed 670G. The device is intended to automatically monitor glucose (sugar) and provide appropriate basal insulin doses.  

    Image Courtesy of Medtronic
  • Abbott gains FDA approval for the Freestyle Libre

    There is no doubt that 2017 was Abbott's year. Fresh off closing its $25 billion dollar acquisition of St. Jude Medical, Abbott celebrated another victory when it scored FDA approval for the Freestyle Libre Flash. The device is a sensor that can monitor glucose without patients having to do a blood draw to measure levels. The approval not only bumped up Abbott's shares , but  also reinvigorated the diabetes space.

    Image Courtesy of Abbott Laboratories
Filed Under
500 characters remaining